Evidence map›Paper›PMID 29262551›Full record

ArticleOncotarget2017

The combination of temozolomide-irinotecan regresses a doxorubicin-resistant patient-derived orthotopic xenograft (PDOX) nude-mouse model of recurrent Ewing's sarcoma with a FUS-ERG fusion and

Kentaro Miyake, Takashi Murakami, Tasuku Kiyuna, Kentaro Igarashi, Kei Kawaguchi, Masuyo Miyake, Yunfeng Li, Scott D Nelson, Sarah M Dry, Michael Bouvet and 11 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
6.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 41 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Tumor-targetingHeliyon · 2018
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 5 institutions in 2 countries.

Kentaro MiyakeAntiCancer Inc., San Diego, CA, USA.
Takashi MurakamiAntiCancer Inc., San Diego, CA, USA.
Tasuku KiyunaAntiCancer Inc., San Diego, CA, USA.
Kentaro IgarashiAntiCancer Inc., San Diego, CA, USA.
Kei KawaguchiAntiCancer Inc., San Diego, CA, USA.
Masuyo MiyakeAntiCancer Inc., San Diego, CA, USA.
Yunfeng LiDepartment of Pathology, University of California, Los Angeles, CA, USA.
Scott D NelsonDepartment of Pathology, University of California, Los Angeles, CA, USA.
Sarah M DryDepartment of Pathology, University of California, Los Angeles, CA, USA.
Michael BouvetDepartment of Surgery, University of California, San Diego, CA, USA.
Irmina A ElliottDivision of Surgical Oncology, University of California, Los Angeles, CA, USA.
Tara A RussellDivision of Surgical Oncology, University of California, Los Angeles, CA, USA.
Arun S SinghDivision of Hematology-Oncology, University of California, Los Angeles, CA, USA.
Mark A EckardtDepartment of Surgery, Yale School of Medicine, New Haven, CT, USA.
Yukihiko HiroshimaDepartment of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Masashi MomiyamaDepartment of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Ryusei MatsuyamaDepartment of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Takashi ChishimaDepartment of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Itaru EndoDepartment of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Fritz C EilberDivision of Surgical Oncology, University of California, Los Angeles, CA, USA.
Robert M HoffmanAntiCancer Inc., San Diego, CA, USA.
University of California, Los Angeles · USUniversity of California, San Diego · USYokohama City University · JPAntiCancer (United States) · USYale University · US

Funding

Establishment of a patient-like mouse models of soft-tissue sarcoma sub-typesR43CA213649 · NCI · ANTICANCER, INC. · PI HOFFMAN, ROBERT M · 2017 to 2017
$225k
NCI NIH HHS R43 CA213649
6 · The paper itself

Abstract

The aim of the present study was to determine the usefulness of a patient-derived orthotopic xenograft (PDOX) nude-mouse model of a doxorubicin-resistant metastatic Ewing's sarcoma, with a unique combination of a FUS-ERG fusion and

Indexed as

Ewing’s sarcomairinotecanpatient-derived orthotopic xenografttemozolomidethird-line chemotherapy

Identifiers

PMID29262551
PMCPMC5732717
OpenAlexW2752301033

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.